Cartilage Regeneration Market Set to Reach $5.62 Billion by 2034, Driven by Advancements in Regenerative Medicine and Minimally Invasive Procedures
Global Cartilage Regeneration Market
Dublin, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The "Cartilage Regeneration Market by Type, by Treatment Modality, by Application Site, by Surgical Procedure, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering.The global cartilage regeneration market accounted for USD 1.16 billion in 2023 and is expected to reach USD 5.62 billion by 2034 with a CAGR of 15.43% during the forecast period 2024-2034. The market will grow due to rising rates of joint disorders, rising demand for minimally invasive procedures, technological advancements in scaffolds and biomaterials, increased sports injuries, and expanding uses in orthopedic and sports medicine.
The orthopedics and sports medicine fields are exploring new uses for cartilage regeneration technology outside of the more conventional ones, such as osteoarthritis. The market is expanding as a result of these therapies' increased use in treating a wider variety of cartilage lesions, such as those caused by degenerative disorders, trauma, and sports injuries. For instance, Smith & Nephew's ReGen Advantage meniscal repair system received FDA 510(k) certification in the United States in February 2024. This minimally invasive technique treats a different kind of knee cartilage injury.By type, the hyaline cartilage segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the high demand for hyaline cartilage regeneration therapies to treat osteoarthritis and sports injuries, coupled with advancements in tissue engineering techniques tailored for hyaline cartilage repair. For instance, Zimmer Biomet and Arthrogenics announced a partnership in April 2024 to develop next-generation cartilage repair solutions using biologic medicines. Additionally, the fibrocartilage segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of fibrocartilage injuries in athletes and active individuals, coupled with ongoing research and development efforts to enhance regenerative therapies specifically targeted towards fibrocartilage repair.By treatment modality, the cell-based segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the efficacy of cell-based therapies in promoting cartilage regeneration and repairing tissue defects, supported by advancements in stem cell research, tissue engineering, and biotechnology. For instance, in March 2024, Anika reports favorable long-term outcomes from a clinical trial including its Hyaluronate Arthroscopy (HA) treatment for osteoarthritis in the knee, indicating promise for supporting cartilage regeneration. Additionally, the stem cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of stem cell-based approaches for cartilage regeneration, driven by their potential to differentiate into chondrocytes and stimulate tissue repair, alongside ongoing clinical trials and advancements in stem cell technology.By application site, the knee segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the prevalence of knee-related cartilage injuries, including osteoarthritis and sports-related trauma, coupled with high demand for effective treatment options and advancements in knee-specific regenerative therapies. For instance, in March 2024, Histogenics announces that it has formed a strategic alliance with a prominent orthopedic company (name withheld) to advance the development of its NeoCart cartilage healing product. Additionally, the shoulder segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of shoulder injuries, particularly in athletes and aging populations, along with advancements in shoulder-specific regenerative therapies and minimally invasive surgical techniques.By surgical procedure, the arthroscopic chondroplasty segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the growing preference for minimally invasive procedures for cartilage repair, coupled with the widespread adoption of arthroscopic chondroplasty techniques for addressing cartilage lesions in various joints. For instance, RTI Surgical announced the full commercial introduction of Meniscal Repair System (MRS), its next-generation meniscal repair solution, in April 2024. Additionally, the autologous chondrocyte implantation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for personalized cartilage repair solutions, advancements in tissue engineering, and the potential of autologous chondrocyte implantation to provide long-term functional outcomes with reduced risk of immune rejection.By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global cartilage regeneration market in 2023 owing to the high patient footfall for orthopedic procedures, availability of advanced surgical facilities, and increasing adoption of cartilage regeneration therapies in hospital and clinic settings. For instance, in March 2024, CollPlant will publish encouraging preclinical data at the Orthopaedic Research Society (ORS) Annual Meeting regarding its Bio-Regen implant for cartilage healing. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient procedures, advancements in minimally invasive surgical techniques, and the convenience and cost-effectiveness offered by ambulatory surgical centers for cartilage regeneration procedures.North America is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of musculoskeletal disorders, robust healthcare infrastructure, increasing adoption of advanced medical technologies, and supportive reimbursement policies for cartilage regeneration therapies in North America. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about cartilage regeneration therapies, increasing healthcare expenditure, expanding geriatric population, and advancements in healthcare infrastructure in the Asia Pacific region. For instance, Orthocell wins CE Mark clearance for its OrthoStrip product in Europe in February 2024. OrthoStrip is a collagen membrane that is utilized for a variety of purposes, including cartilage restoration.This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.Report Scope:
Market Forecast by Type, Treatment Modality. Application Site, Surgical Procedures, and End-User
Market Forecast for 5 Regions and 17+ Countries
North America (U.S. and Canada)
Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
MEA (South Africa, GCC, Rest of MEA)
Company Profiles of the Top 10+ Major Market Players
Vericel
Smith & Nephew
Zimmer Biomet Holdings
Stryker
Anika Therapeutics
Arthrex
Osiris Therapeutics
Histogenics
B. Braun Melsungen
Medtronic
RTI Surgical Holdings
CollPlant Biotechnologies
Orthocell
CONMED
Bioventus
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2023 - 2034
Estimated Market Value (USD) in 2023
$1.16 Billion
Forecasted Market Value (USD) by 2034
$5.62 Billion
Compound Annual Growth Rate
15.4%
Regions Covered
Global
Key Topics Covered: 1. Research Methodology2. Introduction2.1. Market Definition2.2. Global Cartilage Regeneration Market Overview3. Executive Summary4. Market Environment Analysis4.1. Porter's 5 Forces Analysis4.2. PESTEL Analysis4.3. SWOT Analysis5. Market Dynamics5.1. Drivers Analysis5.1.1. Increasing Prevalence of Musculoskeletal Disorders5.1.2. Advancements in Regenerative Medicine5.1.3. Preference for Minimally Invasive Procedures5.1.4. Expanding Applications in Orthopedic and Sports Medicine5.2. Restraints Analysis5.2.1. High Cost of Treatment5.2.2. Regulatory Hurdles5.2.3. Risk of Complications5.3. Opportunities Analysis5.3.1. Untapped markets in emerging economies5.3.2. Focus on Personalized Medicine5.3.3. Increasing Patient Education and Awareness5.3.4. Growing Telemedicine and Digital Health5.4. Threats Analysis5.4.1. Reimbursement Challenges5.4.2. Intellectual Property Issues5.4.3. Adverse Events and Safety Concerns5.5. Trend Analysis5.5.1. Shift Towards Biologics5.5.2. Focus on Functional Outcomes5.5.3. Rise of Regenerative Rehabilitation5.5.4. Expanded Use of Artificial Intelligence6. COVID-19 Impact Analysis7. Cartilage Regeneration Market: Type Estimates & Trend Analysis7.1. Type Segment Opportunity Analysis7.2. Fibro Cartilage7.3. Hyaline Cartilage7.4. Elastic Cartilage7.5. Other8. Cartilage Regeneration Market: Treatment Modality Estimates & Trend Analysis8.1. Treatment Modality Segment Opportunity Analysis8.2. Cell-Based8.3. Chondrocyte Transplantation8.4. Growth Factor Technology8.5. Non-Cell Based8.6. Tissue Scaffolds8.7. Cell-Free Composites9. Cartilage Regeneration Market: Application Site Estimates & Trend Analysis9.1. Application Site Segment Opportunity Analysis9.2. Knee9.3. Arthroscopic Chondroplasty9.4. Autologous Chondrocyte9.5. Osteochondral Grafts Transplantation9.6. Cell-based Cartilage Resurfacing9.7. Microfracture9.8. Other9.9. Spine9.10. Ankle9.11. Hip9.12. Others10. Cartilage Regeneration Market: Surgical Procedure Estimates & Trend Analysis10.1. Application Site Segment Opportunity Analysis10.2. Chondroplasty10.3. Microfracture10.4. Autologous Chondrocyte Implantation10.5. Osteochondral Autograft Transplantation10.6. Osteochondral Allograft Transplantation10.7. Juvenile Allograft Fragments10.8. Others11. Cartilage Regeneration Market: End-user Estimates & Trend Analysis11.1. End-user Segment Opportunity Analysis11.2. Ambulatory Surgical Centers11.3. Hospitals and Clinics11.4. Surgical Centers11.5. Others12. Regional Market Analysis13. North America Cartilage Regeneration Market14. Europe Global Cartilage Regeneration Market15. Asia Pacific Global Cartilage Regeneration Market16. Latin America Global Cartilage Regeneration Market17. MEA Global Cartilage Regeneration Market18. Competitor Analysis18.1. Company Market Share Analysis, 202318.2. Major Recent Developments19. Company Profiles
Vericel
Smith & Nephew
Zimmer Biomet Holdings
Stryker
Anika Therapeutics
Arthrex
Osiris Therapeutics
Histogenics
B. Braun Melsungen
Medtronic
RTI Surgical Holdings
CollPlant Biotechnologies
Orthocell
CONMED
Bioventus
For more information about this report visit https://www.researchandmarkets.com/r/l3u9ft
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Global Cartilage Regeneration Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 minutes ago
- Business Wire
Thunderbird Entertainment Retains Three Part Advisors for Its Investor Relations Program
VANCOUVER, British Columbia--(BUSINESS WIRE)--Thunderbird Entertainment Group Inc. (TSXV: TBRD, OTCQX: THBRF) (' Thunderbird ' or the ' Company ') is pleased to announce that it has retained Three Part Advisors, LLC (' Three Part Advisors '), a leading full-service, strategic investor relations advisory firm headquartered near Dallas, Texas, for its ongoing investor relationship program, effective July 1, 2025. Three Part Advisors will work closely with management on the Company's strategic investor relations program, with a focus on enhancing Thunderbird's visibility within the investment community. This includes, but is not limited to, identifying and engaging with potential investors, organizing investor presentations and meetings with interested parties, responding to incoming calls from shareholders and potential investors, and providing general capital markets advisory services. Jennifer Twiner McCarron, CEO and Chair of Thunderbird, commented, 'We're pleased to welcome Three Part Advisors as our new strategic investor relations advisory firm. Given our significant growth plans and the health of our business, we believe this is an opportune time to share the Thunderbird story with a broader investor audience.' Steven Hooser, Partner of Three Part Advisors, said, 'We are thrilled to welcome Thunderbird Entertainment to our growing base of diverse clients. We know that introducing the Company to the right investors looking for growth and a strong management team is vital, and Thunderbird has built a global content creation studio of premium, award-winning content and distribution that will generate excitement from fundamental investors across our network.' Three Part Advisors has been retained for an initial period of one year, commencing July 1, 2025, at a rate of $12,500 USD per month. Three Part Advisors has no interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest, other than as described herein. Market Making Services Correction Thunderbird is correcting language from an announcement made on October 23, 2024. The agreement with the Independent Trading Group to provide market making services in accordance with TSX Venture Exchange policies was for an initial term of one month and renewable thereafter. About Three Part Advisors, LLC Three Part Advisors, LLC is a leading full-service, strategic investor relations advisory firm. Through measurable and proactive investor relations programs, the firm helps clients develop their investment thesis, effectively communicate the strategy to Wall Street, meet new investors and ultimately, lower the cost of capital. Three Part Advisors also provides corporate design services and annually holds three independent IDEAS investor conferences ( Unbiased by investment banking fees and trading commissions, Three Part Advisors has a proven reputation for engaging with companies that are supported by strong investment merits and proven fundamentals, and proactively communicating their stories to Wall Street in the most effective manner. More information is available at About Thunderbird Entertainment Thunderbird Entertainment (TSXV: TBRD, OTCQX: THBRF) is a global award-winning, full-service multiplatform production, distribution and rights management company, headquartered in Vancouver, with teams in Los Angeles and Ottawa. Thunderbird creates award-winning scripted, unscripted, and animated programming for the world's leading digital platforms, as well as Canadian and international broadcasters. The Company develops, produces, and distributes animated, factual, and scripted content through its various content arms, including Thunderbird Kids and Family (Atomic Cartoons), Thunderbird Unscripted (Great Pacific Media) and Thunderbird Scripted. Productions under the Thunderbird umbrella include Mermicorno: Starfall, Super Team Canada, Molly of Denali, Highway Thru Hell, Kim's Convenience, Boot Camp and Sidelined: The QB and Me. Thunderbird Distribution and Thunderbird Brands manage global media and consumer products rights, respectively, for the Company and select third parties. Thunderbird is on Facebook, X, and Instagram at @tbirdent. For more information, visit: Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release, which has been prepared by management. Cautionary Statement Regarding Forward-Looking Information Certain statements contained in this news release may contain forward-looking information or may be forward-looking statements (collectively, 'forward-looking statements') within the meaning of applicable securities laws. Forward-looking statements may be identified by words such as 'anticipate', 'continue', 'estimate', 'expect', 'forecast', 'may', 'will', 'plan', 'project', 'should', 'believe', 'intend', or similar expressions concerning matters that are not historical facts. Forward-looking statements in this press release include, but are not limited to, statements regarding Thunderbird's retention of Three Part Advisors, LLC as its new investor relations advisory firm, the anticipated benefits of this engagement, including enhancing Thunderbird's visibility within the investment community, increasing investor awareness and engagement, supporting the Company's growth and shareholder value, and the implementation of a proactive investor awareness program aimed at increasing shareholder engagement, trading volume, and attracting long-term investors. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; product capability and acceptance; international risk and currency exchange rates; and technology changes. The forward-looking statements or information contained in this document represent our views as of the date hereof and as such information should not be relied upon as representing our views as of any date subsequent to the date of this document. The Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements or information.
Yahoo
34 minutes ago
- Yahoo
Xtract One Technologies Inc. Announces $7 Million 'Bought Deal' Public Offering
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES BASE SHELF PROSPECTUS IS ACCESSIBLE AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE ON SEDAR+ WITHIN TWO BUSINESS DAYS TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- June 11, 2025 – Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, (the "Company" or "Xtract One") is pleased to announce that it has entered into an agreement with Ventum Capital Markets (the "Underwriter") pursuant to which the Underwriter has agreed to purchase 18,000,000 units (the "") from the treasury of the Company, at a price of $0.39 per Unit (the 'Issue Price') and offer them to the public by way of prospectus supplement for total gross proceeds of $7,020,000 (the "Offering"). Each Unit will consist of one common share of the Company (each a 'Common Share') and one common share purchase warrant (each full warrant, a 'Warrant' and collectively the 'Warrants'). The Company has granted the Underwriter an option to purchase up to an additional 15% of the Offered Securities at the Issue Price. The Over-Allotment Option may be exercised in whole or in part to purchase Offered Securities as determined by the Underwriter upon written notice to the Company at any time up to 30 days following the Closing Date (the 'Over-Allotment Option'). The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes. The Offered Securities will be offered (i) by way of a prospectus supplement to the base shelf prospectus of the Company dated February 6, 2024 (the 'Base Shelf Prospectus') to be filed in all provinces and territories of Canada, except Quebec (the 'Prospectus Supplement'); (ii) may be distributed in the United States to Qualified Institutional Buyers (as defined in Rule 144A under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act')) pursuant to an exemption under Rule 144A; and (iii) may be distributed outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company's securities under domestic or foreign securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The Offering is expected to close on or about June 18, 2025, or such other date as the Company and the Underwriter may agree, and is subject to customary closing conditions, including the approval of the securities regulatory authorities and the Toronto Stock Exchange. Access to the Prospectus Supplement, the Base Shelf Prospectus and any amendments thereto are provided in Canada in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus supplement and any amendment to such documents. The Base Shelf Prospectus is, and the Prospectus Supplement will be (within two business days from the date hereof), accessible through SEDAR+ at An electronic or paper copy of the Prospectus Supplement, the Base Shelf Prospectus and any amendment thereto may be obtained, without charge, from Ventum Financial Corp., or email at ecm@ by providing the contact with an email address or address, as applicable. About Xtract One Xtract One Technologies is a leading technology-driven provider of threat detection and security solutions leveraging AI to deliver seamless and secure experiences. The Company makes unobtrusive weapons and threat detection systems that are designed to assist facility operators in prioritizing- and delivering improved 'Walk-right-In' experiences while enhancing safety. Xtract One's innovative portfolio of AI-powered Gateway solutions excels at allowing facilities to discreetly screen and identify weapons and other threats at points of entry and exit without disrupting the flow of traffic. With solutions built to serve the unique market needs for schools, hospitals, arenas, stadiums, manufacturing, distribution, and other customers, Xtract One is recognized as a market leader delivering the highest security in combination with the best individual experience. For more information, visit or connect on Facebook, X, and LinkedIn. About Threat Detection Systems Xtract One solutions, when properly configured, deployed, and utilized, are designed to help enhance safety and reduce threats. Given the wide range of potential threats in today's world, no threat detection system is 100% effective. Xtract One solutions should be utilized as one element in a multilayered approach to physical security. For further information, please contact: Xtract One Inquiries: info@ Media Contact: Kristen Aikey, JMG Public Relations, 212-206-1645, kristen@ Investor Relations: Chris Witty, Darrow Associates, 646-438-9385, cwitty@ Forward-Looking InformationThis news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding the anticipated completion of the Offering, intended use of proceeds from the Offering, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking statements'. Forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not expect', 'is expected', 'estimates', 'intends', 'anticipates' or 'does not anticipate', 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company's limited operating history and lack of historical profits; risks related to the Company's business and financial position; fluctuations in the market price of the Company's Common Shares; that the Company may not be able to accurately predict its rate of growth and profitability; the failure of the Company and/or the Underwriter to satisfy closing conditions to the Offering; whether the Over-Allotment Option will be exercised; the failure of the Company to satisfy certain TSX additional listing requirements in respect of the Offered Securities; the failure of the Company to use any of the proceeds received from the Offering in a manner consistent with current expectations; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, clients and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no intention to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason, except as required by law.
Business Wire
37 minutes ago
- Business Wire
Vestis Corporation (VSTS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VESTIS CORPORATION (VSTS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 7, 2025, Vestis released its second quarter fiscal 2025 financial results and revised its prior growth and revenue guidance for 2025, providing guidance for the third quarter, falling significantly below market expectations. The Company explained that the poor results were partially due to 'lost business in excess of new business' but primarily on 'lower adds over stops, which is how [it] describe[s] volumes changes with [its] existing customers.' On this news, Vestis's stock price fell $3.27, or 37.5%, to close at $5.44 per share on May 7, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Vestis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
